Oculis (OCS) 3rd Annual Guggenheim Healthcare Innovation Conference summary
Event summary combining transcript, slides, and related documents.
3rd Annual Guggenheim Healthcare Innovation Conference summary
9 Nov, 2026Pipeline and near-term milestones
Two late-stage assets: privosegtor across neuroprotection indications and licaminlimab, a genotype-based precision medicine program in dry eye disease.
PREDICT-1 top-line results expected within weeks; an IND for the neuro indication was submitted and confirmation was expected in the coming days to weeks.
R&D Day planned for December 8, with a PIONEER-1 execution update, refined PREDICT-1 timing and a broader privosegtor indication-development plan.
Licaminlimab
TNF-inhibitor antibody fragment designed for high concentration and ocular tissue penetration; TNFR1 biomarker aims to identify patients who are more responsive to TNF inhibition.
Across three Phase II trials, the latest symptom study showed exploratory improvement among TNFR1 patients; the latest sign trial showed a prespecified secondary-endpoint effect ~5x all-comers and ~6x the best competing Phase III result.
PREDICT-1 randomized 176 patients, two-thirds TNFR1-positive; enrollment exceeded the 160-patient plan as screened patients already in process were allowed to continue.
Placebo response is managed with a two-week artificial-tears run-in, exclusion of tear responders, a discomfort-score threshold above 60/100 and TNFR1 enrichment.
Management views a good result as doubling the prior 4.3-point drug-placebo difference in TNFR1 patients; responder rate above 25% versus 18% previously in all-comers would be a meaningful benchmark.
Privosegtor
Optic neuritis is the initial orphan indication; management cited no existing treatment and highlighted its value as a neuroprotection model using visual function, OCT structure and biomarkers.
ACUITY Phase II showed an 18-letter LCVA difference maintained through month six, alongside retinal structural preservation and lower neurofilament and GFAP signals; results supported FDA Breakthrough and EMA PRIME designations.
PIONEER-1 is tracking to plan; the goal is 30 of 60 sites activated by year-end, ahead of the December-to-May seasonal period for relapses and optic neuritis.
PIONEER-1 uses LCVA as its endpoint, with LCVA 2.5%, GCIPL and neurofilament as secondary measures and GFAP exploratory.
FDA alignment calls for two studies to provide 300 exposed patients; PIONEER-1/2 support optic neuritis, while PIONEER-2/3 support acute MS relapse, including ambulatory relapse in PIONEER-3.
Latest events from Oculis
- Privosegtor advances neuroprotection while licaminlimab tests biomarker-guided dry-eye care.OCS
Stifel 2026 Healthcare Conference 2026 - Late-stage trials advance as $252.0M in cash supports runway into 2H 2029.OCS
Q3 2026 - ACUITY signals support a registrational optic neuritis program for privosegtor.OCS
Euretina Innovation Spotlight (EIS) 2026 Presentation - TNFR1-guided dry-eye development targets greater benefit in biomarker-positive patients.OCS
Study presentation - Phase III programs in dry eye and optic neuritis advance, with MS and NAION expansion planned.OCS
2026 Global Healthcare Conference - Precision medicine and targeted trials drive clinical and commercial strategy, with strong funding.OCS
H.C. Wainwright 28th Annual Global Investment Conference - Privosegtor and Licaminlimab trials advance, with strong cash reserves supporting long-term growth.OCS
Q2 2026 - Late-stage neuro-ophthalmic and ophthalmic programs advance toward pivotal milestones with strong financial backing.OCS
Corporate presentation - Positive clinical results and precision medicine advances set the stage for major milestones in 2024–2025.OCS
H.C. Wainwright 26th Annual Global Investment Conference